All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
In the era of upfront quadruplets, is there still a role for allogeneic transplant?
Featured
Bookmark this article
During the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub was pleased to speak to Morie A. Gertz, Mayo Clinic, Rochester, US. We asked, In the era of upfront quadruplets, is there still a role for allogeneic transplant?
In the era of upfront quadruplets, is there still a role for allogeneic transplant?
In this video, Gertz discusses the fall in allogeneic transplantation for patients with multiple myeloma in the US due to the increasing availability of less toxic agents, such as CAR T cells and bi-specific antibodies. Gertz also discusses the risk of chronic GvHD after transplant in multiple myeloma and long-term survival outcomes.
Related articles
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox